Assenagon Asset Management S.A. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Assenagon Asset Management S.A. purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 96,629 shares of the biopharmaceutical company's stock, valued at approximately $2,343,000. Assenagon Asset Management S.A. owned approximately 0.08% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 580 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Catalyst Pharmaceuticals by 6.2% during the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 875 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after buying an additional 952 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after buying an additional 1,000 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock traded down $0.41 during trading hours on Thursday, reaching $22.81. 1,465,950 shares of the company traded hands, compared to its average volume of 1,135,181. The firm has a 50-day moving average price of $23.94 and a 200 day moving average price of $22.89. The company has a market cap of $2.78 billion, a P/E ratio of 14.53, a P/E/G ratio of 0.93 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.58.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the sale, the insider now owns 42,681 shares of the company's stock, valued at $1,127,205.21. The trade was a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CPRX shares. Stephens reaffirmed an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Six investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.